In this Forum we'll learn what policies could improve digital equity across individuals and communities.
This virtual event explored how the justice system and mental health and social supports can work together to identify more equitable paths to recovery and reentry into society.
In this Forum we learned what policies could improve our effectiveness at helping people get and stay stably housed, and how to improve the health of individuals and our communities.
This two-part virtual forum series explored how to strengthen the public health system and foster connections between public health and health care delivery systems.
Schools systems have the power to improve the health of a whole community, and COVID-19 shed light on the critical intersection between health and education. This virtual event will explore how health and education professionals can collaboratively and sustainably build healthy schools. Attendees will learn about school funding, community engagement strategies, and developing a long-term plan to prioritize and embed health in schools.
Telehealth gives us a glimpse into our health care future – but public and private sector choices will determine whether telehealth fully lives up to its promise.
This webinar is the second in a two-part series that looks at racial equity in the drug development system, from investment all the way through access. This forum will focus on equity in the patent system, clinical trials, healthcare delivery, and affordability.
Kaiser Permanente’s Institute for Health Policy invites you to join a two-part virtual forum examining racial equity in the drug development system, from research all the way through to access. This first conversation on December 7 will specifically explore racial inequities in drug investment and research and identify new directions for the future.
This event brought together school and early childhood professionals to discuss how to mitigate and address trauma across children’s lifespans.
This event brought together leaders from across sectors to advance the conversation on defining and assessing drug value and elevate policy opportunities that encourage a value-based approach to drug pricing.